Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Extended Release Centanafadine in Healthy Young Adults
NCT02827513Phase 1Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of centanafadine in attention deficit hyperactivity disorder (ADHD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Treatment Emergent Adverse Events up to 12 days. Started Dec 2015; status: terminated.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02827513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02827513.